- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00180505
ASSESS Study: Evaluation of ABSOLUTE™ Stent System for Occluded Arteries
Non-Randomized, Prospective, Multi-center Evaluation of the ABSOLUTE™ .035 Peripheral Self-Expanding Stent System for Occluded or Stenotic Superficial Femoral or Proximal Popliteal Arteries
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
The treatment of stenosis in superficial femoral arteries and/or proximal popliteal arteries with stenting is associated with high restenosis rates, especially with the first generation stents (stainless steel). Currently, self-expandable nitinol stents are commercialized which lead to higher primary patency rates as compared to the first generation stents, even in longer lesions. However, until now most data available are retrospective and uni-center. The ASSESS study is a prospective multi-center study investigating the performance (restenosis rate, patency rates) of the ABSOLUTE™. 035 peripheral self-expandable stent in longer lesions (lesion length from 4.00 mm to 200.00 mm).
Moreover, literature shows stent fracture in nitinol stents, with a possible clinical relationship. For this reason, the ASSESS study will analyze the stent fractures of the ABSOLUTE™ stent, and a possible relationship between stent fracture and restenosis.
Studietype
Inschrijving (Verwacht)
Fase
- Fase 4
Contacten en locaties
Studie Locaties
-
-
-
Namur, België, 5000
- CHR de Namur
-
-
-
-
-
Bad Krozingen, Duitsland, 79189
- Herzzentrum Bad Krozingen
-
Hamburg, Duitsland, 22527
- Universitäres Herz & Gefässzentrum Hamburg
-
Leipzig, Duitsland, 04289
- Herzzentrum Leipzig
-
-
-
-
-
Essey les Nancy, Frankrijk, 54270
- Polyclinique Louis Pasteur
-
Rennes Cedex, Frankrijk, 35033
- Hôpital Pontchaillou- CHU
-
-
-
-
-
Thessaloniki, Griekenland, 57001
- Papageorgiou Hospital
-
-
-
-
-
Baggiovara (Modena), Italië, 41100
- Nuovo Ospedale Civile Sant' Agostino
-
Mercogliano, Italië, 83013
- Casa di Cura Montevergine
-
Pavia, Italië, 27100
- Policlinico San Matteo
-
-
-
-
-
Klagenfurt, Oostenrijk, 9026
- Landeskrankenhaus Klagenfurt
-
Wien, Oostenrijk, 1090
- Allgemeines Krankenhaus der Stadt Wien (AKH Wien)
-
-
-
-
-
Donostia-San Sebastian, Spanje, 20014
- Hospital de Donostia
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
De novo lesion of the superficial femoral artery (SFA) or proximal popliteal artery within the following parameters:
- 10 mm distal to the origin of the profunda femoris (= 10 mm from the femoral bifurcation in the SFA) and
- 20 mm from the proximal margin of the intercondylar fossa.
- Patients must have symptomatic leg ischemia, requiring treatment of the superficial femoral/proximal popliteal vessel
- Target vessel reference diameter visually estimated to be > 4.0 mm and < 7.0 mm
- Target lesion length visually estimated to be > 40 mm and < 200 mm
- If the patient has a contralateral SFA or contralateral proximal popliteal lesion, this lesion can be treated as a non-target lesion. The time and way of treatment of the non-target lesion will be left up to the discretion of the investigator
- At least one-vessel run-off to the foot confirmed by baseline angiography
- Patent common iliac artery, common femoral artery and profunda confirmed by baseline angiography. The patent common iliac artery can be obtained during the index procedure by a successful treatment prior to the treatment of the target lesion. Successful treatment being defined as attainment of final residual diameter stenosis of < 30% without death, stroke, bleeding requiring > 2 units transfusion, or any other complication which was device or procedure related.
- Patient is acceptable candidate for femoral-popliteal artery bypass surgery
Exclusion Criteria:
- Previous ipsilateral femoro-popliteal or femoro-tibial surgery
- Presence of a stent in the target vessel
- Prescheduled staged procedures of multiple lesions within the ipsilateral iliac or ipsilateral popliteal arteries within 30 days after the index procedure
- Co-existing aneurysmal disease of the abdominal aorta or iliac or popliteal arteries
- Acute thrombophlebitis or deep vein thrombus
- Any immunosuppressive disorders, groin infection, or acute systemic infection due to any cause or any viral or bacterial infection
- Significant gastrointestinal (GI) bleed within the past month that would contraindicate the use of anti-platelet therapy
- Hemodynamic instability
- Target lesion is restenotic from previous intervention
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Ander: 1
The purpose of the ASSESS Registry is to investigate the performance of the ABSOLUTE™ .035
Peripheral Self-Expanding Stent System (ABSOLUTE™ Stent) in preventing restenosis of occluded or stenotic superficial femoral or proximal popliteal arteries.
|
A prospective, non-randomized, multi-center study to investigate the performance of the ABSOLUTE™ .035
Peripheral Self-Expanding Stent System (ABSOLUTE™ Stent) in preventing restenosis of occluded or stenotic superficial femoral or proximal popliteal arteries.
Follow up at 30, 180, 270, 365 days and 2 years.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Restenosis rate (diameter stenosis ≥ 50% as determined by Duplex ultrasound).
Tijdsspanne: At 180 days
|
At 180 days
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Clinically driven target lesion revascularization
Tijdsspanne: at 12 and 24 month follow-up
|
at 12 and 24 month follow-up
|
Target lesion primary, primary assisted and secondary patency rates
Tijdsspanne: at 6, 12 and 24 month follow-up
|
at 6, 12 and 24 month follow-up
|
Major complications
Tijdsspanne: at 1, 6, 12 and 24 month follow-up
|
at 1, 6, 12 and 24 month follow-up
|
Angiographic binary restenosis rate in a subset of patients
Tijdsspanne: at 9 month follow-up
|
at 9 month follow-up
|
Device and procedure success
Tijdsspanne: Acute
|
Acute
|
Vascular and bleeding complications (local and puncture site)
Tijdsspanne: 1, 6, 12, 24 months
|
1, 6, 12, 24 months
|
Stent fracture determined by biplane X-ray
Tijdsspanne: at 12 month follow-up
|
at 12 month follow-up
|
Restenosis rate at 365 days, and 2 years (diameter stenosis ≥ 50% as determined by Duplex ultrasound)
Tijdsspanne: 365 days and 2 years
|
365 days and 2 years
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Thomas Zeller, M.D., Herzzentrum Bad Krozingen, Germany
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 04-100
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Perifere vaataandoeningen
-
Mayo ClinicAanmelden op uitnodigingAnatomie van de GSV voor Rescue Peripheral IV AccessVerenigde Staten
-
University of PennsylvaniaVoltooidPatiënten met primaire of secundaire diagnose Code of Intrntl Classification of Diseases, 9th Revision, (ICD-9-CM) 410 (Behalve wanneer het 5e cijfer 2 was)Verenigde Staten
-
SpringWorks Therapeutics, Inc.VerkrijgbaarNeurofibromatose Type 1-geassocieerde plexiforme neurofibromen | Histiocytisch neoplasma | Andere MAP-K Pathway Driven Diseases
Klinische onderzoeken op ABSOLUTE™: Self-Expandable Peripheral Nitinol Stent
-
Provascular GmbHBoston Scientific CorporationVoltooidPerifere arteriële aandoeningen | Oppervlakkige stenose van de femorale arterieDuitsland
-
Cordis CorporationVoltooidArteriële occlusieve ziektenVerenigd Koninkrijk
-
Samsung Medical CenterTaewoong Medical Co., Ltd.OnbekendUreterale obstructieKorea, republiek van